Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the ...
As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors ...
Get key Q3 2025 earnings insights for Abbott Labs (ABT)—discover growth drivers, innovation highlights, and outlook for 2026.
"Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said Robert Ford, ...
Abbott (NYSE: ABT) shares dipped before hours today on third-quarter results that fell short of the consensus Wall Street ...
Abbott Labs reported 6.9% sales growth in Q3 2025, led by medical devices and nutrition, while reaffirming full-year guidance ...
InvestorsHub on MSN
Abbott Shares Dip After In-Line Q3 Results, Full-Year Outlook Reaffirmed
Abbott Laboratories (NYSE:ABT) shares fell more than 2% in premarket trading on Wednesday after the healthcare and medical devices company reported third-quarter earnings that came in line with ...
Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in ...
In 2022, a shutdown at an Abbott infant formula plant in Michigan sparked a nationwide baby formula shortage. Abbott’s global pediatric nutrition sales fell 19% in 2022, but have been growing since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback